European Society for Medical Oncology (ESMO)

This phase 2 trial investigates the efficacy and safety of anlotinib combined with fulvestrant in patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer, focusing on secondary hormone resistance. Read More ›

This indirect treatment comparison evaluates the efficacy and outcomes of imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in estrogen receptor (ER)-positive/HER2-negative advanced breast cancer, based on data from 3 phase 3 trials. Read More ›

The phase 2 TACTIVE-N trial evaluates the efficacy and safety of vepdegestrant, a proteolysis-targeting chimera estrogen receptor (ER) degrader, versus anastrozole in postmenopausal patients with ER-positive/HER2-negative localized breast cancer. Read More ›

The monarchE trial investigates the prognostic and predictive value of Ki-67 index pre- and post-neoadjuvant chemotherapy, focusing on changes following treatment in hormone receptor (HR)-positive/HER2-negative localized breast cancer patients. Read More ›

Subgroup analysis from the phase 3 CAPItello-291 study evaluates the efficacy of capivasertib combined with fulvestrant as first- and second-line endocrine-based therapy in patients with PIK3CA/AKT1/PTEN-altered hormone receptor (HR)-positive advanced breast cancer, focusing on treatment outcomes. Read More ›

This quality initiative focuses on improving care pathways for patients with hormone receptor (HR)-positive/HER2-negative, node-positive early breast cancer at high risk of recurrence, addressing diagnostic optimization, treatment strategies, and long-term outcomes in real-world practice. Read More ›

The phase 2 AGAIN study examines abemaciclib rechallenge in patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer who have progressed on abemaciclib plus endocrine therapy, providing data on feasibility and outcomes. Read More ›

The VIKTORIA-1 trial evaluates gedatolisib with fulvestrant, with or without palbociclib, compared with fulvestrant alone in patients with hormone receptor (HR)-positive/HER2-negative/PIK3CA wild-type advanced breast cancer, offering early insights into treatment approaches. Read More ›

The OptiTROP-Breast02 trial examines sacituzumab tirumotecan versus investigator’s choice chemotherapy in previously treated hormone receptor (HR)-positive/HER2-negative advanced breast cancer, focusing on treatment strategies for this population. Read More ›

This real-world analysis investigates the relationship between ESR1-positivity rates and the length of exposure to endocrine therapy with or without cyclin-dependent kinase (CDK)4/6 inhibitors in hormone receptor (HR)-positive/HER2-negative breast cancer. Read More ›